PE20090426A1 - Composicion vacunal homogenea para el tratamiento del cancer y su metodo de obtencion - Google Patents
Composicion vacunal homogenea para el tratamiento del cancer y su metodo de obtencionInfo
- Publication number
- PE20090426A1 PE20090426A1 PE2008001089A PE2008001089A PE20090426A1 PE 20090426 A1 PE20090426 A1 PE 20090426A1 PE 2008001089 A PE2008001089 A PE 2008001089A PE 2008001089 A PE2008001089 A PE 2008001089A PE 20090426 A1 PE20090426 A1 PE 20090426A1
- Authority
- PE
- Peru
- Prior art keywords
- hregf
- cancer
- treatment
- homogenic
- rp64k
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000008240 homogeneous mixture Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
REFERIDA A UNA COMPOSICION VACUNAL QUE COMPRENDE: A) UN CONJUGADO PROTEICO hrEGF-Rp64K, CARACTERIZADA PORQUE CADA MOLECULA DE PROTEINA Rp64k TIENE ENLAZADA DOS MOLECULAS DE hrEGF Y ESTAN EN UNA PROPORCION DE 12,04 nMOLES DE PROTEINA rP64k POR 24.05 nMOLES DE hrEGF; B) UN ADYUVANTE SELECCIONADO DE HIDROXIDO DE ALUMINIO Y MONTANIDE. DICHO CONJUGADO ES UNA MEZCLA HOMOGENEA LIBRE DE GLUTARALDEHIDO Y ESPECIES MOLECULARES COMO POLIMEROS DE hrEGF O hrEGF LIBRE. DICHA COMPOSICION INDUCE UN INCRMENTO DE AL MENOS 100 VECES EL TITULO DE ANTICUERPOS ANTI-EGF EN EL SUERO DE HUMANOS, SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON EL CRECIMIENTO CELULAR COMO TUMORES Y CANCER
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20070154A CU23652A1 (es) | 2007-06-29 | 2007-06-29 | Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090426A1 true PE20090426A1 (es) | 2009-05-05 |
Family
ID=40225717
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013000227A PE20131037A1 (es) | 2007-06-29 | 2008-06-26 | COMPOSICION INMUNOGENICA QUE COMPRENDE UN CONJUGADO hrEGF-rP64k |
PE2008001089A PE20090426A1 (es) | 2007-06-29 | 2008-06-26 | Composicion vacunal homogenea para el tratamiento del cancer y su metodo de obtencion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013000227A PE20131037A1 (es) | 2007-06-29 | 2008-06-26 | COMPOSICION INMUNOGENICA QUE COMPRENDE UN CONJUGADO hrEGF-rP64k |
Country Status (31)
Country | Link |
---|---|
US (2) | US8778879B2 (es) |
EP (1) | EP2184072B1 (es) |
JP (1) | JP5368437B2 (es) |
KR (1) | KR20100039372A (es) |
CN (1) | CN101790383B (es) |
AR (1) | AR067085A1 (es) |
AT (1) | ATE536885T1 (es) |
AU (1) | AU2008271798B2 (es) |
BR (1) | BRPI0813662B8 (es) |
CA (1) | CA2692340C (es) |
CL (1) | CL2008001936A1 (es) |
CO (1) | CO6251274A2 (es) |
CU (1) | CU23652A1 (es) |
CY (1) | CY1112476T1 (es) |
DK (1) | DK2184072T3 (es) |
EA (1) | EA021905B1 (es) |
ES (1) | ES2379130T3 (es) |
HK (1) | HK1145979A1 (es) |
HR (1) | HRP20120218T1 (es) |
JO (1) | JO2777B1 (es) |
MY (1) | MY149136A (es) |
NZ (1) | NZ582829A (es) |
PE (2) | PE20131037A1 (es) |
PL (1) | PL2184072T3 (es) |
PT (1) | PT2184072E (es) |
RS (1) | RS52196B (es) |
SI (1) | SI2184072T1 (es) |
TW (1) | TWI409080B (es) |
UY (1) | UY31184A1 (es) |
WO (1) | WO2009003425A1 (es) |
ZA (1) | ZA201000609B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU20200032A7 (es) * | 2020-06-09 | 2022-01-13 | Ct Inmunologia Molecular | Composiciones vacunales basadas en nano-partículas de fosfatos de calcio para el tratamiento del cáncer |
CN114594257B (zh) * | 2022-05-09 | 2022-08-05 | 北京生物制品研究所有限责任公司 | 含CpG ODN的吸附型疫苗的解吸附组合物及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0657175B1 (en) | 1993-12-09 | 2005-03-02 | Centro de Inmunologia Molecular | Vaccine comprising human autologous epidermal growth factor and use thereof |
CA2261433A1 (en) * | 1993-12-09 | 1995-06-10 | Belinda Sanchez Ramirez | Composition comprising autologous epidermal growth factor |
CU23077A1 (es) * | 2000-12-06 | 2005-08-17 | Centro Inmunologia Molecular | Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas |
CU22979A1 (es) * | 2000-12-08 | 2004-09-09 | Centro Inmunologia Molecular | Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina |
CU22999A1 (es) * | 2001-12-04 | 2004-10-12 | Centro Inmunologia Molecular | Método de tratamiento de enfermedades malignas e infecciosas crónicas |
GB0109297D0 (en) * | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
FR2844514B1 (fr) * | 2002-09-16 | 2007-10-19 | Neovacs | Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation |
GB0405787D0 (en) * | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
-
2007
- 2007-06-29 CU CU20070154A patent/CU23652A1/es unknown
-
2008
- 2008-06-20 AR ARP080102638A patent/AR067085A1/es not_active Application Discontinuation
- 2008-06-26 KR KR1020107002173A patent/KR20100039372A/ko active Search and Examination
- 2008-06-26 JP JP2010513634A patent/JP5368437B2/ja active Active
- 2008-06-26 CA CA2692340A patent/CA2692340C/en active Active
- 2008-06-26 PL PL08757902T patent/PL2184072T3/pl unknown
- 2008-06-26 AT AT08757902T patent/ATE536885T1/de active
- 2008-06-26 PE PE2013000227A patent/PE20131037A1/es not_active Application Discontinuation
- 2008-06-26 RS RS20120101A patent/RS52196B/en unknown
- 2008-06-26 BR BRPI0813662A patent/BRPI0813662B8/pt active IP Right Grant
- 2008-06-26 ES ES08757902T patent/ES2379130T3/es active Active
- 2008-06-26 NZ NZ582829A patent/NZ582829A/en active IP Right Revival
- 2008-06-26 PE PE2008001089A patent/PE20090426A1/es not_active Application Discontinuation
- 2008-06-26 EA EA201070080A patent/EA021905B1/ru not_active IP Right Cessation
- 2008-06-26 AU AU2008271798A patent/AU2008271798B2/en active Active
- 2008-06-26 EP EP08757902A patent/EP2184072B1/en active Active
- 2008-06-26 UY UY31184A patent/UY31184A1/es unknown
- 2008-06-26 MY MYPI20095626A patent/MY149136A/en unknown
- 2008-06-26 SI SI200830563T patent/SI2184072T1/sl unknown
- 2008-06-26 WO PCT/CU2008/000005 patent/WO2009003425A1/es active Application Filing
- 2008-06-26 DK DK08757902.5T patent/DK2184072T3/da active
- 2008-06-26 PT PT08757902T patent/PT2184072E/pt unknown
- 2008-06-26 TW TW097123928A patent/TWI409080B/zh active
- 2008-06-26 CN CN200880021856XA patent/CN101790383B/zh active Active
- 2008-06-26 US US12/664,545 patent/US8778879B2/en active Active
- 2008-06-27 CL CL2008001936A patent/CL2008001936A1/es unknown
- 2008-06-29 JO JO2008307A patent/JO2777B1/en active
-
2009
- 2009-12-18 CO CO09145155A patent/CO6251274A2/es active IP Right Grant
-
2010
- 2010-01-27 ZA ZA201000609A patent/ZA201000609B/xx unknown
-
2011
- 2011-01-10 HK HK11100165.6A patent/HK1145979A1/xx unknown
-
2012
- 2012-01-10 US US13/346,831 patent/US8841251B2/en active Active
- 2012-03-07 HR HR20120218T patent/HRP20120218T1/hr unknown
- 2012-03-09 CY CY20121100245T patent/CY1112476T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119925T1 (el) | Aνti-cd40 αντισωματα, χρησεις και μεθοδοι | |
BR112018015238A2 (pt) | conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição | |
CY1115076T1 (el) | ΕΝΑ ANTΙ-PDGFRα ΑΝΤΙΣΩΜΑ ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΜΕΤΑΣΤΑΤΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΩΝ ΟΣΤΩΝ | |
BR112018013407A2 (pt) | anticorpos e conjugados dos mesmos | |
CY1117963T1 (el) | Αντισωματα που προσδενουν τα il-17a και il-17f | |
BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
CR9512A (es) | Metodos para el tratamiento de tumores de cerebro con anticuerpos | |
BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
EA200900040A1 (ru) | Молекулы антител, которые связываются с человеческим il-17 | |
AR069903A1 (es) | Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer | |
ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
CO6680656A2 (es) | Anticuerpos para metaloproteinasa -9 de matriz | |
BR112012028326A2 (pt) | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos | |
AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
ATE521366T1 (de) | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen | |
AR059809A1 (es) | Anticuerpos anti-5t4 y sus usos | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
AR051484A1 (es) | Moleculas de anticuerpo que tienen especificidad para la il - 17 humana | |
BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
CL2007003649A1 (es) | Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70. | |
EA201991763A1 (ru) | Конъюгаты антитела к ccr7 и лекарственного средства | |
EA201190041A1 (ru) | Человеческие аутоантитела против альфа-синуклеина | |
CO6260094A2 (es) | Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos | |
CO2018003852A2 (es) | Proteínas de unión a antigeno que activan el receptor de leptina | |
CO6280500A2 (es) | Anticuerpos humanizados especificos pare l factor von willebrand |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |